MBX Biosciences, Inc. Common Stock (MBX) Stock

MBX Biosciences, Inc. Common Stock (MBX) is a Healthcare stock trading at $43.04 (as of 2026-06-18), with a market capitalization of $1.50B and a trailing P/E of -16.4. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company developing precision peptide therapies for endocrine and metabolic conditions. Its pipeline includes MBX 2109 for chronic hypoparathyroidism, MBX 1416 for post-bariatric hypoglycemia, and MBX 4291 for obesity, with candidates in Phase 2, Phase 1, and preclinical development, respectively.

Valuation — source: SEC EDGAR (first-party)
Price$43.04
Market Cap$1.50B
P/E Ratio-16.4
EV / EBITDA-16.7
Price / Book3.86
DCF Value (model)$-27.75
DCF Upside vs Price-164.5%
Profitability & Growth — source: SEC EDGAR
Return on Equity-19.8%
Current Ratio30.79
Valuation vs Sector & Industry
Stock P/E-16.4
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector-178.1%
vs Industry-194.8%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderFrazier Life Sciences Management, L.P. ($198.56M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOPeter Kent Hawryluk
Employees43
CountryUS
IPO Date2000-01-14

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Oruka Therapeutics, Inc. (ORKA)
  • Relay Therapeutics, Inc. (RLAY)
  • Collegium Pharmaceutical, Inc. (COLL)
  • Rapport Therapeutics, Inc. Common Stock (RAPP)
  • Ardelyx, Inc. (ARDX)
  • Tyra Biosciences, Inc. (TYRA)
  • Immatics N.V. (IMTX)
  • AnaptysBio, Inc. (ANAB)
MBX earnings history · MBX institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.